| 2026-03-25 |
详情>>
内部人交易：
Abbey Donald股份减少704.00股
|
| 2026-02-19 |
详情>>
股本变动：
变动后总股本2469.03万股
|
| 2026-02-19 |
详情>>
业绩披露：
2025年年报每股收益0.03美元,归母净利润73.20万美元,同比去年增长100.62%
|
| 2026-02-19 |
财报披露：
美东时间 2026-02-19 盘后发布财报
|
| 2025-11-06 |
详情>>
业绩披露：
2025年三季报(累计)每股收益0.67美元,归母净利润1646.60万美元,同比去年增长117.54%
|
| 2025-08-07 |
详情>>
业绩披露：
2025年中报每股收益0.81美元,归母净利润1986.20万美元,同比去年增长132.63%
|
| 2025-05-08 |
详情>>
业绩披露：
2025年一季报每股收益-0.63美元,归母净利润-1547.6万美元,同比去年增长60.79%
|
| 2025-04-03 |
股东大会：
将于2025-05-13召开股东大会
会议内容 ▼▲
- 1.Elect the following seven directors of the Company to serve until the next annual meeting of stockholders or until their successors have been elected and qualified: Vivek Jain, David C. Greenberg, Elisha W. Finney, David F. Hoffmeister, Donald M. Abbey, Laurie Hernandez, and Kolleen T. Kennedy.
2.Consider a proposal to approve an amendment to the Amended and Restated ICU Medical, Inc. 2011 Stock Incentive Plan;
3.Ratify the appointment of Deloitte & Touche LLP as the independent registered public accounting firm for the Company for the year ending December 31, 2025;
4.Hold an advisory vote to approve our named executive officer compensation;
5.Hold an advisory vote on a stockholder proposal to adopt simple majority voting;
6.Transact such other business as may properly come before the Annual Meeting or any adjournment thereof.
|
| 2025-02-27 |
详情>>
业绩披露：
2024年年报每股收益-4.83美元,归母净利润-1.18亿美元,同比去年增长-296.86%
|
| 2025-02-27 |
详情>>
业绩披露：
2022年年报每股收益-3.11美元,归母净利润-7428.6万美元,同比去年增长-172.03%
|
| 2024-11-12 |
详情>>
业绩披露：
2023年三季报(累计)每股收益-0.52美元,归母净利润-1250.8万美元,同比去年增长78.71%
|
| 2024-11-12 |
详情>>
业绩披露：
2024年三季报(累计)每股收益-3.85美元,归母净利润-9386万美元,同比去年增长-650.4%
|
| 2024-08-07 |
详情>>
业绩披露：
2024年中报每股收益-2.51美元,归母净利润-6087.7万美元,同比去年增长-208.3%
|
| 2024-05-07 |
详情>>
业绩披露：
2024年一季报每股收益-1.63美元,归母净利润-3947.1万美元,同比去年增长-302.27%
|
| 2024-04-02 |
股东大会：
将于2024-05-15召开股东大会
会议内容 ▼▲
- 1.Elect the following seven directors of the Company to serve until the next annual meeting of stockholders or until their successors have been elected and qualified: Vivek Jain, David C. Greenberg, Elisha W. Finney, David F. Hoffmeister, Donald M. Abbey, Laurie Hernandez, and Kolleen T. Kennedy.
2.Ratify the appointment of Deloitte & Touche LLP as the independent registered public accounting firm for the Company for the year ending December 31, 2024;
3.Hold an advisory vote to approve our named executive officer compensation;
4.Transact such other business as may properly come before the Annual Meeting or any adjournment thereof.
|
| 2024-02-27 |
详情>>
业绩披露：
2023年年报每股收益-1.23美元,归母净利润-2965.5万美元,同比去年增长60.08%
|
| 2023-11-07 |
复牌提示：
2023-11-07 09:30:34 停牌，复牌日期 2023-11-07 09:35:34
|
| 2023-04-04 |
股东大会：
将于2023-05-17召开股东大会
会议内容 ▼▲
- 1.Elect the following nine directors of the Company to serve until the next annual meeting of stockholders or until their successors have been elected and qualified: Vivek Jain, George A. Lopez, M.D., David C. Greenberg, Elisha W. Finney, David F. Hoffmeister, Donald M. Abbey, Laurie Hernandez, Kolleen T. Kennedy and William Seeger.
2.Consider a proposal to approve an amendment to the Amended and Restated ICU Medical, Inc. 2011 Stock Incentive Plan by;
3.Ratify the appointment of Deloitte & Touche LLP as the independent registered public accounting firm for the Company for the year ending December 31, 2023;
4.Hold an advisory vote to approve our named executive officer compensation;
5.Hold an advisory vote to determine the frequency of future advisory votes on our named executive officer compensation;
6.Transact such other business as may properly come before the Annual Meeting or any adjournment thereof.
|
| 2022-04-04 |
股东大会：
将于2022-05-17召开股东大会
会议内容 ▼▲
- 1.To elect the following nine directors of the Company to serve until the next annual meeting of stockholders or until their successors have been elected and qualified: Vivek Jain, George A. Lopez, M.D., David C. Greenberg, Elisha W. Finney, David F. Hoffmeister, Donald M. Abbey, Laurie Hernandez, Kolleen T. Kennedy and William Seeger.
2.To ratify the appointment of Deloitte & Touche LLP as the independent registered public accounting firm for the Company for the year ending December 31, 2022;
3.To hold an advisory vote to approve our named executive officer compensation;
4.To transact such other business as may properly come before the Annual Meeting or any adjournment thereof.
|
| 2021-09-06 |
温馨提示：
美股因劳工节，9月6日休市一天
|
| 2021-04-01 |
股东大会：
将于2021-05-11召开股东大会
会议内容 ▼▲
- 1.To elect the following seven directors of the Company to serve until the next annual meeting of stockholders or until their successors have been elected and qualified: Vivek Jain, George A. Lopez, M.D., Robert S. Swinney, M.D., David C. Greenberg, Elisha W. Finney, Donald M. Abbey and David F. Hoffmeister.
2.To ratify the selection of Deloitte & Touche LLP as the independent registered public accounting firm for the Company for the year ending December 31, 2021;
3.To hold an advisory vote to approve our named executive officer compensation;
4.To transact such other business as may properly come before the Annual Meeting or any adjournment thereof.
|
| 2020-04-03 |
股东大会：
将于2020-05-13召开股东大会
会议内容 ▼▲
- 1.To elect the following seven directors of the Company to serve until the next annual meeting of stockholders or until their successors have been elected and qualified: Vivek Jain, George A. Lopez, M.D., Robert S. Swinney, M.D., David C. Greenberg, Elisha W. Finney, Donald M. Abbey and David F. Hoffmeister.
2.To ratify the selection of Deloitte & Touche LLP as the independent registered public accounting firm for the Company for the year ending December 31, 2020;
3.To hold an advisory vote to approve our named executive officer compensation;
4.To transact such other business as may properly come before the Annual Meeting or any adjournment thereof.
|
| 2019-04-05 |
股东大会：
将于2019-05-15召开股东大会
会议内容 ▼▲
- 1.To elect the following seven directors of the Company to serve until the next annual meeting of stockholders or until their successors have been elected and qualified: Vivek Jain, George A. Lopez, M.D., Robert S. Swinney, M.D., David C. Greenberg, Elisha W. Finney, Donald M. Abbey and David F. Hoffmeister.
2.To ratify the selection of Deloitte & Touche LLP as the independent registered public accounting firm for the Company for the year ending December 31, 2019;
3.To hold an advisory vote to approve our named executive officer compensation;
4.To transact such other business as may properly come before the Annual Meeting or any adjournment thereof.
|
| 2018-04-05 |
股东大会：
将于2018-05-15召开股东大会
会议内容 ▼▲
- 1.To elect the following eight directors of the Company to serve until the next annual meeting of stockholders or until their successors have been elected and qualified: Vivek Jain, George A. Lopez, M.D., Robert S. Swinney, M.D., David C. Greenberg, Elisha W. Finney, Douglas E. Giordano, Donald M. Abbey and David F. Hoffmeister.
2.To ratify the selection of Deloitte & Touche LLP as the independent registered public accounting firm for the Company for the year ending December 31, 2018;
3.To hold an advisory vote to approve our named executive officer compensation; 4.To transact such other business as may properly come before the Annual Meeting or any adjournment thereof.
|
| 2017-04-10 |
股东大会：
将于2017-05-09召开股东大会
会议内容 ▼▲
- 1.To elect the following eight directors of the Company to serve until the next annual meeting of stockholders or until their successors have been elected and qualified: Vivek Jain, George A. Lopez, M.D., Joseph R. Saucedo, Richard H. Sherman, M.D., Robert S. Swinney, M.D., David C. Greenberg, Elisha W. Finney, and Douglas E. Giordano.
2.To consider a proposal to approve the Amended and Restated ICU Medical, Inc. 2011 Stock Incentive Plan, including an increase to the number of shares under the plan by 1,425,000 shares to 4,179,510 shares;
3.To ratify the selection of Deloitte & Touche LLP as the independent registered public accounting firm for the Company for the year ending December 31, 2017;
4.To hold an advisory vote to approve our named executive officer compensation;
5.To hold an advisory vote to determine the frequency of future advisory votes on our named executive officer compensation;
6.To transact such other business as may properly come before the Annual Meeting or any adjournment thereof.
|
| 2016-04-04 |
股东大会：
将于2016-05-16召开股东大会
会议内容 ▼▲
- 1. To elect seven directors of the Company to serve for a term of one year or until their successors have been elected and qualified;
2. To ratify the selection of Deloitte & Touche LLP as the independent registered public accounting firm for the Company for the year ending December 31, 2016;
3. To hold an advisory vote to approve our named executive officer compensation;
4. To transact such other business as may properly come before the Annual Meeting or any adjournment thereof.
|
| 2015-05-08 |
股东大会：
将于2015-06-15召开股东大会
会议内容 ▼▲
- 1. To elect six directors of the Company to serve for a term of one year or until their successors have been elected and qualified;
2. To ratify the selection of Deloitte & Touche LLP as the independent registered public accounting firm for the Company for the year ending December 31, 2015;
3. To hold an advisory vote to approve our named executive officer compensation;
4. To transact such other business as may properly come before the Annual Meeting or any adjournment thereof.
|